LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 106 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $12,892 | -38.7% | 10,925 | -26.8% | 0.00% | -20.0% |
Q2 2023 | $21,044 | -36.0% | 14,925 | -31.9% | 0.01% | -44.4% |
Q1 2023 | $32,888 | -30.4% | 21,925 | -26.7% | 0.01% | -35.7% |
Q4 2022 | $47,282 | +63.0% | 29,925 | +20.1% | 0.01% | +55.6% |
Q3 2022 | $29,000 | -39.6% | 24,925 | -16.7% | 0.01% | -35.7% |
Q2 2022 | $48,000 | 0.0% | 29,925 | -3.2% | 0.01% | +16.7% |
Q1 2022 | $48,000 | -38.5% | 30,925 | -3.1% | 0.01% | -33.3% |
Q4 2021 | $78,000 | +8.3% | 31,925 | +10.4% | 0.02% | 0.0% |
Q3 2021 | $72,000 | -12.2% | 28,925 | -0.3% | 0.02% | -14.3% |
Q2 2021 | $82,000 | +9.3% | 29,000 | -9.4% | 0.02% | 0.0% |
Q1 2021 | $75,000 | +36.4% | 32,000 | +3.2% | 0.02% | +31.2% |
Q4 2020 | $55,000 | +2650.0% | 31,000 | +6.9% | 0.02% | – |
Q3 2020 | $2,000 | -92.0% | 29,000 | 0.0% | 0.00% | -100.0% |
Q2 2020 | $25,000 | 0.0% | 29,000 | -5.5% | 0.01% | -25.0% |
Q1 2020 | $25,000 | +31.6% | 30,700 | +44.8% | 0.01% | +71.4% |
Q4 2019 | $19,000 | +5.6% | 21,200 | +16.5% | 0.01% | 0.0% |
Q3 2019 | $18,000 | – | 18,200 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 34,935,485 | $39,477,000 | 3.01% |
Raffles Associates | 2,080,536 | $2,351,000 | 2.51% |
Defender Capital, LLC. | 5,184,035 | $5,862,000 | 2.30% |
Prescott General Partners LLC | 1,851,851 | $2,093,000 | 0.16% |
DAFNA Capital Management LLC | 140,000 | $158,000 | 0.04% |
Fort Sheridan Advisors LLC | 83,931 | $95,000 | 0.03% |
Long Focus Capital Management, LLC | 215,000 | $243,000 | 0.02% |
XTX Topco Ltd | 72,807 | $82,000 | 0.02% |
Ergoteles LLC | 490,895 | $555,000 | 0.02% |
Beirne Wealth Consulting Services, LLC | 45,000 | $51,000 | 0.02% |